- Home
- KRUS vs BDTX Comparison
KRUS vs BDTX Comparison
Compare KRUS & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRUS | BDTX |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 683.6M | 148.1M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KRUS | BDTX |
|---|---|---|
| Price | $51.97 | $2.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $84.29 | $10.60 |
| AVG Volume (30 Days) | 309.1K | ★ 1.6M |
| Earning Date | 01-07-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.38 |
| Revenue | ★ $282,763,000.00 | $70,000,000.00 |
| Revenue This Year | $18.91 | N/A |
| Revenue Next Year | $20.16 | N/A |
| P/E Ratio | ★ N/A | $6.59 |
| Revenue Growth | ★ 18.88 | N/A |
| 52 Week Low | $40.03 | $1.20 |
| 52 Week High | $106.60 | $4.94 |
Technical Indicators
Market Signals| Indicator | KRUS | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.85 | 31.10 |
| Support Level | $53.00 | $2.52 |
| Resistance Level | $56.62 | $2.69 |
| Average True Range (ATR) | 2.39 | 0.12 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 22.92 | 7.32 |
Price Performance
Historical ComparisonAbout KRUS Kura Sushi USA Inc.
Kura Sushi USA Inc is a technology-enabled Japanese restaurant concept that provides guests with a distinctive dining experience by serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. The company operates a network of dine-in locations across the U.S. states and Washington, DC.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.